Astroskin First Flight with Virgin Galactic and Kellie Gerardi

Washington, DC, USA (June 3rd, 2021): Virgin Galactic has announced a new contract to fly International Institute of Astronautical Sciences (IIAS) researcher Kellie Gerardi on a test flight of the company’s spaceflight system, during which Kellie will conduct experiments and test new healthcare technologies (including the Astroskin Bio-Monitor) while she’s in space. Continue reading

Phoenix Innovators are Driving Translational Discovery

It is challenging to find anyone who has not had their life impacted by cancer, a debilitating illness, or a degenerative condition.  These diseases affect not only the patient’s life, but those of their families and their surrounding community. The advancement of medicine is changing this trajectory, and that advancement will go right through Phoenix.Continue reading

Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform

Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform
Accelerates Caris’ rapid growth as the market leader reshaping precision oncology through basic science research and the application of artificial intelligence to one of the largest clinico-genomic databases

Capital raise represents one of the largest private financings in precision medicine supported by a diverse, high-quality syndicate of leading investorsContinue reading

C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Continue reading